Zobrazeno 1 - 10
of 335
pro vyhledávání: '"LYMPHODEPLETION"'
Autor:
Jing Guo, Chunyan Wang, Ning Luo, Yuliang Wu, Wei Huang, Jihui Zhu, Weihui Shi, Jinye Ding, Yao Ge, Chunhong Liu, Zhen Lu, Robert C. Bast, Guihai Ai, Weihong Yang, Rui Wang, Caixia Li, Rong Chen, Shupeng Liu, Huajun Jin, Binghui Zhao, Zhongping Cheng
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background Tumor-infiltrating lymphocyte (TIL) therapy has been restricted by intensive lymphodepletion and high-dose intravenous interleukin-2 (IL-2) administration. To address these limitations, we conducted preclinical and clinical studie
Externí odkaz:
https://doaj.org/article/47172d00ce154c1d97952eab624ecce7
Autor:
Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R. Chong, Eugenio Fardella, Elise A. Chong, Giulia Gabrielli, Sunita D. Nasta, Daniel J. Landsburg, Jordan Carter, Raymone Pajarillo, Stefan K. Barta, Griffin White, Elizabeth Weber, Ellen Napier, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Marco Ruella
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-5 (2024)
Abstract Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CA
Externí odkaz:
https://doaj.org/article/7841086f48d141fcacd16214fbafb379
Autor:
Wai Lun Will Pak, Natalie A. Brumwell, Charlene C. Kabel, Victoria Gutgarts, Insara Jaffer Sathick, Sham Mailankody, Alexander M. Lesokhin, Heather J. Landau, Aisha Shaikh
Publikováno v:
Kidney Medicine, Vol 6, Iss 8, Pp 100856- (2024)
Chimeric antigen receptor (CAR) T-cell therapy against B-cell maturation antigen is a new treatment modality for relapsed or refractory multiple myeloma (MM). Patients with kidney failure and MM were excluded from the pivotal CAR T-cell therapy clini
Externí odkaz:
https://doaj.org/article/b441d1d4e60349e08b3cb758bb808407
Publikováno v:
Cancer Medicine, Vol 13, Iss 11, Pp n/a-n/a (2024)
Abstract Chimeric antigen receptor T‐cell (CAR‐T) therapy is becoming an effective technique for the treatment of patients with relapsed/refractory hematologic malignancies. After analyzing patients with tumor progression and sustained remission
Externí odkaz:
https://doaj.org/article/7d2b0559f6314471904be29d615c780b
Autor:
David G. Frame, Marcus Geer, Salena Kasha, Denise Markstrom, Gianni Scappaticci, Tate Feeney, Andrew Hayduk, Hilary M. Mansoor, Avery Oberfeld, Hannah D’Antonio, Sarah Anand, Sung Won Choi, John Maciejewski, Attaphol Pawarode, Mary Mansour Riwes, Muneesh Tewari, John Magenau, Monalisa Ghosh
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionLymphodepleting chemotherapy (LDC) is critical to CAR T-cell expansion and efficacy. Despite this, there is not a consensus in the literature regarding the optimal LDC regimen, including dose and frequency.MethodsWe retrospectively review
Externí odkaz:
https://doaj.org/article/fed4b8bf17fe48edb13b4dc2a67474d8
Autor:
Yunju Ma, Haiping Dai, Qingya Cui, Sining Liu, Liqing Kang, Xiaying Lian, Wei Cui, Jia Yin, Lingling Liu, Mengjie Cai, Lei Yu, Depei Wu, Xiaowen Tang
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-5 (2023)
Abstract Relapse is a major limitation of chimeric antigen receptor (CAR) T-cell therapy. Here, we speculated that decitabine (DAC) in combination with fludarabine and cyclophosphamide (FC) as a lymphodepletion regimen may improve the efficacy of CD1
Externí odkaz:
https://doaj.org/article/6b94a466e83746c0801f60736378202b
Autor:
Benno Lickefett, Lulu Chu, Valentin Ortiz-Maldonado, Linda Warmuth, Pere Barba, Matteo Doglio, David Henderson, Michael Hudecek, Andreas Kremer, Janet Markman, Magdalena Nauerth, Helene Negre, Carmen Sanges, Philipp B. Staber, Rebecca Tanzi, Julio Delgado, Dirk H. Busch, Jürgen Kuball, Maik Luu, Ulrich Jäger
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Lymphodepletion (LD) or conditioning is an essential step in the application of currently used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it maximizes engraftment, efficacy and long-term survival of CAR-T. Its mai
Externí odkaz:
https://doaj.org/article/867d97eccd50488c8737f46f9637a5f0
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 3 (2023)
ABSTRACTTo overcome challenges associated with adoptive cell therapy (ACT), we developed a personalized autologous T-cell therapy program. Patients with advanced cancer with HLA-A *02:01 allele and tumor expression of PRAME, MAGEA1, MAGEA4, MAGEA8, N
Externí odkaz:
https://doaj.org/article/feb043363ffc49cca62e71ac4fff02e9
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The most common lymphodepletion regimen used prior to infusion of chimeric antigen receptor-T cells (CAR-T) is cyclophosphamide (CY) in combination with fludarabine (Flu) (CY-FLU). While cyclophosphamide (CY) possesses lymphotoxic effects, it concurr
Externí odkaz:
https://doaj.org/article/24b09a070b8647b692e9057acaa497be
Autor:
Franziska Marquard, Claudia Langebrake, Dietlinde Janson, Maida Mahmud, Adrin Dadkhah, Nicolaus Kröger, Francis Ayuk
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Acute kidney injury and chronic kidney disease is common in multiple myeloma. Fludarabine which is part of lymphodepletion before CAR-T cell therapy is renally eliminated and its use is not recommended for patients with severe renal impairment define
Externí odkaz:
https://doaj.org/article/4362855007ef4f0fbff98299b509a757